Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | Director · Executive Chair | August 20, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 302,214 |
Last balance in matching sequence
After 2026-08-20 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-08-20 · Sale · Disposed 19,308 · Balance 309,662 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2: This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Row 2 · 2026-08-20 · Sale · Disposed 7,351 · Balance 302,311 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F4: This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Row 3 · 2026-08-20 · Sale · Disposed 97 · Balance 302,214 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
F2: This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
F4: This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2022 Filed Mar 11, 2022 00:28 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,149 | $406.06 | $1,278,672.55 |
DisclosureSEC source: 0001093557-22-000053 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,719 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 00:28 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 16,251 | $0.00 | $16.25 |
DisclosureSEC source: 0001093557-22-000053 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,868 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 01:09 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,000 | $418.04 | $1,254,120.00 |
DisclosureSEC source: 0001093557-22-000018 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,617 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 19,674 | $435.06 | $8,559,370.44 |
DisclosureSEC source: 0001093557-22-000002 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,617 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:35 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 38,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000002 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,291 F3 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2019 that vested on January 18, 2022, with the applicable performance achieved. F3 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2019 that vested on January 18, 2022, with the applicable performance achieved. F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,000 | $438.81 | $1,316,430.00 |
DisclosureSEC source: 0001093557-22-000002 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,705 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 50 | $543.83 | $27,191.50 |
DisclosureSEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 14 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,705 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 50 | $542.06 | $27,103.00 |
DisclosureSEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 13 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,755 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $541.39 | $108,278.00 |
DisclosureSEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 12 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,805 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F12 · price: This transaction was executed in multiple trades at prices ranging from $541.06 to $541.785. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $540.40 | $108,080.50 |
DisclosureSEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 11 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,005 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $539.96 to $540.94. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 179 | $539.32 | $96,538.94 |
DisclosureSEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 10 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,205 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $538.74 to $539.56. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 527 | $538.15 | $283,602.99 |
DisclosureSEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 9 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,384 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $537.59 to $538.47. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 271 | $537.08 | $145,547.92 |
DisclosureSEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 8 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,911 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $536.53 to $537.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $536.01 | $134,002.00 |
DisclosureSEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,182 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $535.47 to $536.395. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $534.84 | $267,421.50 |
DisclosureSEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,432 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $534.32 to $535.14. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $532.92 | $53,292.00 |
DisclosureSEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,932 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 300 | $531.87 | $159,559.77 |
DisclosureSEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,032 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $531.45 to $532.11. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 25 | $530.44 | $13,261.00 |
DisclosureSEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,332 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 148 | $529.78 | $78,406.94 |
DisclosureSEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,357 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $529.35 to $530.15. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $528.06 | $105,612.80 |
DisclosureSEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,505 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $527.75 to $528.59. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 18:11 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 50 | $654.00 | $32,700.00 |
DisclosureSEC source: 0001093557-21-000257 · edgardoc.xml · nonDerivative · entry 8 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,705 F3 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 18:11 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 50 | $652.36 | $32,618.00 |
DisclosureSEC source: 0001093557-21-000257 · edgardoc.xml · nonDerivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,755 F3 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 18:11 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 878 | $649.02 | $569,837.54 |
DisclosureSEC source: 0001093557-21-000257 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,805 F3 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $648.64 to $649.475. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 18:11 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,350 | $647.92 | $874,694.70 |
DisclosureSEC source: 0001093557-21-000257 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,683 F3 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $647.64 to $648.53. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 18:11 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $646.58 | $129,315.00 |
DisclosureSEC source: 0001093557-21-000257 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,033 F3 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $646.57 to $646.58. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 18:11 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $645.01 | $161,251.50 |
DisclosureSEC source: 0001093557-21-000257 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,233 F3 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $644.99 to $645.02. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 18:11 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 222 | $644.59 | $143,098.67 |
DisclosureSEC source: 0001093557-21-000257 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,483 F3 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $643.86 to $644.68. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 18:11 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-21-000257 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,705 F1 · shares: The transaction represents a gift by the Reporting Person of 3,000 shares to a charitable donor advised fund. F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 23:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 614 | $555.71 | $341,207.78 |
DisclosureSEC source: 0001093557-21-000239 · edgardoc.xml · nonDerivative · entry 9 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,705 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $555.68 to $556.085. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 23:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 350 | $554.73 | $194,154.35 |
DisclosureSEC source: 0001093557-21-000239 · edgardoc.xml · nonDerivative · entry 8 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,319 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $554.63 to $555.42. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 23:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $553.14 | $110,628.00 |
DisclosureSEC source: 0001093557-21-000239 · edgardoc.xml · nonDerivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,669 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $553.13 to $553.15. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 23:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 851 | $550.93 | $468,838.71 |
DisclosureSEC source: 0001093557-21-000239 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,869 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $550.80 to $551.09. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 23:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 120 | $549.95 | $65,994.40 |
DisclosureSEC source: 0001093557-21-000239 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,720 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $549.73 to $550.15. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 23:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 681 | $548.71 | $373,668.17 |
DisclosureSEC source: 0001093557-21-000239 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,840 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $548.41 to $549.31. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 23:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 939 | $547.76 | $514,343.54 |
DisclosureSEC source: 0001093557-21-000239 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,521 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $547.395 to $548.26. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 23:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,246 | $546.71 | $681,205.02 |
DisclosureSEC source: 0001093557-21-000239 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,460 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $546.34 to $547.28. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 23:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 999 | $545.84 | $545,294.16 |
DisclosureSEC source: 0001093557-21-000239 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,706 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $545.25 to $546.23. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 613 | $544.07 | $333,512.64 |
DisclosureSEC source: 0001093557-21-000231 · edgardoc.xml · nonDerivative · entry 8 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,705 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $543.74 to $544.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 932 | $543.18 | $506,241.71 |
DisclosureSEC source: 0001093557-21-000231 · edgardoc.xml · nonDerivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,318 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $542.69 to $543.66. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,252 | $541.88 | $678,437.89 |
DisclosureSEC source: 0001093557-21-000231 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,250 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $541.48 to $542.44. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 640 | $540.92 | $346,187.20 |
DisclosureSEC source: 0001093557-21-000231 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,502 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $540.44 to $541.33. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 700 | $539.59 | $377,711.32 |
DisclosureSEC source: 0001093557-21-000231 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,142 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $539.310 to $540.135. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 413 | $538.63 | $222,455.97 |
DisclosureSEC source: 0001093557-21-000231 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,842 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $538.20 to $539.16. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,050 | $537.45 | $564,320.51 |
DisclosureSEC source: 0001093557-21-000231 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,255 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $537.13 to $537.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 400 | $536.49 | $214,594.52 |
DisclosureSEC source: 0001093557-21-000231 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,305 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $536.13 to $536.92. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,982 | $541.36 | $1,614,335.52 |
DisclosureSEC source: 0001093557-21-000218 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,705 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 35 | $541.27 | $18,944.45 |
DisclosureSEC source: 0001093557-21-000218 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,687 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,331 | $386.04 | $513,819.24 |
DisclosureSEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,722 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 300 | $384.91 | $115,473.00 |
DisclosureSEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,053 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $382.48 | $191,240.00 |
DisclosureSEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,353 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.